Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
6.62
-0.14 (-2.07%)
May 9, 2025, 10:37 AM - Market open
DAWN Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for DAWN stock have an average target of 31.57, with a low estimate of 25 and a high estimate of 40. The average target predicts an increase of 376.89% from the current stock price of 6.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $30 → $27 | Strong Buy | Maintains | $30 → $27 | +307.85% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +443.81% | Apr 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $39 → $27 | Strong Buy | Maintains | $39 → $27 | +307.85% | Mar 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $39 → $34 | Buy | Maintains | $39 → $34 | +413.60% | Mar 5, 2025 |
| Wedbush | Wedbush | Buy Reiterates $32 | Buy | Reiterates | $32 | +383.38% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
159.03M
from 131.16M
Increased by 21.25%
Revenue Next Year
259.59M
from 159.03M
Increased by 63.23%
EPS This Year
-1.59
from -1.02
EPS Next Year
-0.78
from -1.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 177.7M | 341.3M | 477.8M | ||
| Avg | 159.0M | 259.6M | 403.2M | ||
| Low | 132.8M | 174.4M | 281.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 35.5% | 114.6% | 84.0% | ||
| Avg | 21.2% | 63.2% | 55.3% | ||
| Low | 1.2% | 9.6% | 8.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.11 | 0.79 | ||
| Avg | -1.59 | -0.78 | 0.45 | ||
| Low | -2.70 | -2.61 | 0.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.